I-123 MIBG cardiac imaging in diabetic neuropathy before and after epalrestat therapy

Clinical Nuclear Medicine

Volumn 24, Issue 6, 1999, Pages 418-420

  Utsunomiya, Keita ^a   Narabayashi, Isamu ^a   Nakatani, Yuko ^b   Tamura, Koji ^b   Onishi, Satoshi ^b  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b Keihanna Hospital   (Japan)

Author keywords

Aldose Reductase Inhibitor; Autonomic Disorder; I 123 Metaiodobenzylguanidine (MIBG); Myocardial Scintigraphy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; EPALRESTAT;

ADULT; ARTICLE; CASE REPORT; DIABETES MELLITUS; DIABETIC NEUROPATHY; DRUG EFFECT; HEART INNERVATION; HEART SCINTISCANNING; HUMAN; MALE; RADIOISOTOPE DISTRIBUTION; SYMPATHETIC INNERVATION;

3-IODOBENZYLGUANIDINE; ADULT; ALDEHYDE REDUCTASE; AUTONOMIC NERVOUS SYSTEM DISEASES; DIABETIC NEUROPATHIES; ENZYME INHIBITORS; HEART; HUMANS; MALE; RADIOPHARMACEUTICALS; RHODANINE; THIAZOLIDINES;

EID: 0032914043     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-199906000-00008     Document Type: Article

References (19)

1. Appenzeller O, Richardson EP Jr: The sympathetic chain in patients with diabetic and alcoholic polyneuropathy. Neurology 16:1205, 1966.
2. Kline RC, Swanson DP, Wieland DM, et al: Myocardial imaging in man with I-123-metaiodobenzylguanidine. J Nucl Med 21:129, 1981.
3. Mäntysaari M, Kuikka J, Mustonen J, et al: Noninvasive detection of cardiac sympathetic nervous dysfunction in diabetic patients using [123I] metaiodobenzylguanidine. Diabetes 41:1069, 1992.
4. Nagamachi S, Hoshi H, Ohnishi T, et al: Evaluation of myocardial scintigraphy using 123I-MIBG in diabetic patients: In regards to autonomic neuropathy. Jap J Nucl Med 31:1059, 1994.
5. Sisson JC, Shaprio B, Meyers I, et al: Metaiodobenzylguanidine to map scintigraphically the adrenergic nervous system in man. J Nucl Med 28:1625, 1987.
6. Wieland DM, Jiann-Iong W, Brown LE, et al: Radiolabeled adrenergic neuron-blocker agents: Adrenomedullary imaging with [131I] iodobenzylguanide. J Nucl Med 21:349, 1980.
7. Schofer J, Spielmann R, Schuchert A, et al: Iodine-123 metaiodobenzylguanidine scintigraphy: A noninvasive method to demonstrate myocardial adrenergic nervous system disintegrity in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol 12:1252, 1988.
8. Goto Y, Hotta N, Shigeta Y, et al: A placebo-controlled double-blind study of epalrestat (ONO-2235) in patients with diabetic neuropathy. Diabet Med 10:39, 1993.
9. Terashima H, Hama K, Yamamoto R, et al: Effects of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther 229:226, 1984.
10. Hashimoto H, Satoh N, Takiguchi Y, et al: Effects of an aldose reductasc inhibitor, ONO-2235, insulin and their combination on the altered responsiveness to the nerve stimulation and agonists of the isolated atria of diabetic rats. J Pharmacol Exp Ther 253:552, 1990.
11. Imamura Y, Ando H, Mitsuoka W, et al: Iodine-123-metaiodobenzylguanidine images reflect intense myocardial adrenergic nervous activity in congestive heart failure independent of underlying cause. J Am Coll Cardiol 26:1594, 1995.
12. Goto Y, Abe R, Nakagawa S, et al: The 3rd report of the etiologic study on diabetic osteopenia: Complications of diabetes in Japan. Tonyobyo (Jpn Diab Soc) (in Japanese) 32:9, 1989.
13. Ewing DJ, Campbell IW, Clarke BF: Mortality in diabetic autonomic neuropathy. Lancet i:601, 1976.
14. Kahn JK, Sisson JC, Vinik AI: QT interval prolongation and sudden death in diabetic autonomic neuropathy. J Clin Endocrinol Metab 64:751, 1987.
15. Ewing DJ, Martyn CN, Young BJ, et al: The value of cardiovascular autonomic function test: 10 years experience in diabetes. Diabetes Care 8:491, 1985.
16. Gabby KH: Hyperglycemia, polyol metabolism and complications of diabetes mellitus. Ann Rev Med 26:521, 1975.
17. Greene DA, Lattimer SA, et al: Glucose induced alterations in nerve metabolism: Current perspective on the pathogenesis of diabetic neuropathy and future directions for research and therapy. Diabetes Care 8:290, 1985.
18. Dvornik D: Aldose Reductase Inhibition: An Approach to the Prevention of Diabetic Complications. New York: McGraw-Hill, 1987.
19. Hotta N, Sakamoto N: Aldose reductase inhibitors. In: Alberti KGMM, Krall LP, eds. The Diabetes Annual/5. Amsterdam: Elsevier, 1990, pp 330-61.